ClinicalTrials.gg
TerminatedNCT02992418Updated Mar 25, 2022Results posted

Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

A Phase 3 interventional study of CYD Dengue Vaccine and Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed in Dengue Fever and Dengue Hemorrhagic Fever, sponsored by Sanofi Pasteur, a Sanofi Company. Terminated at 4 sites in Philippines. Open to participants aged 9 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-25.

Primary conditionSevere DengueRegistry: DengueReclassifiedWhy we changed it
Registry
Dengue — the first condition term the registry derived for this study.
ClinicalTrials.gg
Severe Dengue
Why
  1. The study's listed conditions name Severe Dengue, a narrower term within Dengue.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

How we know

Why this study was terminated
No answer received from the Philippines Food and Drug Administration on protocol amendment issued due to IDMC recommendations. CYD vaccine 3rd dose not given.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
688
Allocation
Randomized
Ages
9 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Severe Dengue by Sanofi — none open to participants now, none under way, none of them phase 3. Severe Dengue · Sanofi.

Enrollment
9th of 26
688 · median 345
Started
2016
with 6 others
Phase 3
9 of 29
none open now
Registered
28th of 29
by date

Among the 29 studies in Severe Dengue by Sanofi, this one is the 9th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2016, is one of 9 in phase 3, and was the 28th registered.

Severe Dengue

65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.

Browse Severe Dengue studies →

Open to participants now

None of the 29 studies in Severe Dengue by Sanofi is open now. The open studies under Severe Dengue, anywhere →

Who these studies take

Of the 4 Severe Dengue studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 9 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Severe Dengue by Sanofi as a file.
02

Study summary

The aim of the study was to investigate the immunogenicity and safety of CYD dengue vaccine and Tetanus Toxoid (T), Reduced Diphtheria Toxoid (D) and Acellular Pertussis Vaccine Adsorbed (ap) (Tdap) vaccine when both vaccines were administered concomitantly or sequentially.

Primary Objectives:

  • To demonstrate the non-inferiority of the humoral immune response to the Tdap booster dose concomitantly administered with the first dose of CYD dengue vaccine as compared to sequential administration, measured 28 days after Tdap booster dose.
  • To demonstrate the non-inferiority of the humoral immune response to the first dose of CYD dengue vaccine concomitantly administered with Tdap as compared to sequential administration, measured 28 days after the first dose of CYD dengue vaccine.

Secondary Objectives:

  • To demonstrate the non-inferiority of the humoral immune response of 3 doses of CYD dengue vaccine with the first dose concomitantly administered with Tdap as compared to sequential administration, measured 28 days after the third dose of CYD dengue vaccine.
  • To describe the humoral immune response at baseline and 28 days after the first and third doses of CYD dengue vaccine, in each and any group.
  • To describe the humoral immune response of Tdap vaccine at baseline and 28 days after concomitant administration with the first dose of CYD dengue vaccine as compared to the sequential administration, in each and any group.
  • To describe the safety of the CYD dengue vaccine and of the Tdap booster dose after each and any injection in each group.
Read the detailed description

Participants were to receive CYD dengue vaccine according to a 3-dose schedule administered 6 months apart, with the first dose of CYD dengue vaccine administered either concomitantly or sequentially with a booster dose of the Tdap vaccine, Adacel®.

During the conduct of the study, a safety signal was identified which led to the Independent Data Monitoring Committee (IDMC) recommendation not to vaccinate participants who had never been infected by dengue prior to the first injection, i.e., dengue non-immune participants. The protocol was amended accordingly but never implemented due to absence of response of Health Authorities (HA) from The Philippines.

After having waited for more than 1.5 years, and as the participants became out of window to complete their immunization schedule and the last safety follow-up call (6 months after the last dose), the Sponsor decided to stop the trial. Participants only attended a last safety follow-up visit to terminate the study and were informed about the end of the study. As a consequence, the study was prematurely terminated before injection of the last dose (3rd dose) of the CYD dengue vaccine.

As a consequence of the IDMC recommendations, the main immunogenicity analyses were done in dengue immune participants which is not what was planned in the protocol (and this is why the primary endpoints are not exactly the same as those defined in the protocol as they were finally assessed only in dengue immune participants whereas initially it was planned to be assessed regardless of baseline status).

All participants were assessed for immunogenicity and safety. Safety assessments included solicited reactions within 7 or 14 days after each injection, unsolicited adverse events within 28 days after each injection, and serious adverse events during the study period.

03

Conditions studied

  • Dengue Fever
  • Dengue Hemorrhagic Fever

Browse trials for

Keywords

  • Dengue Fever
  • Dengue Hemorrhagic Fever
  • CYD Dengue Vaccine
  • Dengavaxia®
04

In context

Severe Dengue Reclassified

65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.

This study's enrollment of 688 is above the median of 170 across 52 interventional studies indexed under Severe Dengue.

Browse Severe Dengue studies →

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Compared within Severe Dengue, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dengue. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
9 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant aged 9 to 60 years (i.e., from the day of the 9th birthday to the day prior to the 61th birthday) on the day of inclusion.
  • Participant in good health, based on medical history and physical examination.
  • form (ICF) or assent form was signed and dated by the participant (based on local regulations), and/or ICF was signed and dated by the parent(s) or another legally acceptable representative (and by an independent witness if required by local regulations).
  • For participant aged 9 to 11 years: known (documented) receipt of at least 4 previous doses of diphtheria toxoid, tetanus toxoid and acellular pertussis-containing (DTaP) vaccines, with the last dose not within the last 5 years prior to enrolment.

OR For participant aged at least 12 years: known (documented or self-reported) receipt of at least 3 previous doses of diphtheria toxoid, tetanus toxoid, and whole cell pertussis-containing (DTwP) vaccines, with the last dose not within the last 5 years prior to enrolment.

  • Participant (or participant and parent[s]/legally acceptable representatives) was able to attend all scheduled visits and complied with all trial procedures.

Exclusion criteria

Exclusion Criteria:

  • Participant was pregnant, or lactating, or of (to be considered of non-childbearing potential, a female must be pre-menarche or for at least 1 year, surgically sterile, or using an effective method of or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination).
  • Participation at the time of study enrollment (or in the 4 weeks preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
  • Planned receipt of any vaccine in the 4 weeks following any trial vaccination.
  • Previous vaccination against dengue disease with the trial CYD dengue vaccine.
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response.
  • Known or suspected congenital or acquired immunodeficiency (including (HIV) infection with impaired immune function); or receipt of therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • A previous severe reaction to pertussis, diphtheria or tetanus vaccine including immediate anaphylaxis, encephalopathy within 7 days or seizure within 3 days of receiving the vaccine.
  • Known systemic to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances.
  • Thrombocytopenia, contraindicating IM vaccination.
  • Bleeding disorder or receipt of anticoagulants within 3 weeks preceding inclusion, which might be a for IM vaccination, at the discretion of the Investigator.
  • Deprived of freedom by administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Current alcohol abuse or drug addiction that, based on Investigator's judgment, may interfere with the participant's ability to comply with trial procedures.
  • Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with trial conduct or completion.
  • Identified as an Investigator or employee of the Investigator with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
  • Self-reported HIV, , or infection.
  • Personal history of Guillain-Barré syndrome.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
688 participants (actual)

Study arms

  • Experimental
    Concomitant Administration Group

    Participants will be administered the first dose of CYD dengue vaccine concomitantly with a dose of Tdap vaccine.

    Biological: CYD Dengue Vaccine · Biological: Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed

  • Experimental
    Sequential Administration Group

    Participants will be administered the first dose of CYD dengue vaccine 28 days after a dose of Tdap vaccine.

    Biological: CYD Dengue Vaccine · Biological: Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed

Interventions

  • BiologicalCYD Dengue Vaccine

    0.5 milliliter (mL), Subcutaneous at Month 1, 7 and Month 13, respectively

    Also known as: Dengvaxia®

  • BiologicalTdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed

    Drug page: AdacelStudies of AdacelAdacel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    0.5 mL, intramuscularly (IM) at Month 1.

    Also known as: Adacel®

  • BiologicalTdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed

    Drug page: AdacelStudies of AdacelAdacel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    0.5 mL, intramuscularly at Day 0.

    Also known as: Adacel®

07

What researchers measure

Primary outcomes

  1. Geometric Mean Concentrations (GMCs) of Antibodies Against Pertussis Antigens (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae 2+3) 28 Days After Dose of Tdap Vaccine in Previously Dengue Immune Participants

    GMCs against each pertussis antigens (pertussis toxoid \[PT\], filamentous hemagglutinin \[FHA\], pertactin \[PRN\], fimbriae types 2 and 3 \[FIM2+3\]) were assessed using an enzyme-linked immunosorbent assay (ELISA) method and were measured in ELISA unit/milliliter (EU/mL). Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.

    Time frame: 28 days after Tdap vaccination

  2. Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants

    Seroprotection against diphtheria (Anti-D) and tetanus (Anti-T) antigens was performed by Micrometabolic Inhibition Test - Toxin Neutralization assay (MIT-TNA) and ELISA, respectively. Seroprotection was defined as anti-D and anti-T Ab concentration greater than 0.1 international units (IU)/mL. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.

    Time frame: 28 days after Tdap vaccination

  3. Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants

    The GMTs against each of the four parenteral dengue virus serotypes (1, 2, 3 and 4) of CYD dengue vaccine were assessed using the 50% plaque reduction neutralization test (PRNT50) assay method. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain. Titers were measured in terms of 1/dilution.

    Time frame: 28 days after first CYD dengue vaccination

Secondary outcomes

  1. Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype at Baseline and 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants

    The GMTs against each of the four parenteral dengue virus serotypes (1, 2, 3 and 4) of CYD dengue vaccine were assessed using PRNT50 assay method. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain. Titers were measured in terms of 1/dilution.

    Time frame: Baseline (Pre-CYD vaccination 1) and 28 days after the first CYD dengue vaccination

  2. Percentage of Participants With Neutralizing Antibody Titers Against Each of the 4 Dengue Virus Serotypes of CYD at Baseline and 28 Days After First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants

    The GMTs against each of the four parenteral dengue virus serotypes (1, 2, 3 and 4) of CYD dengue vaccine were assessed using PRNT50 assay method. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.

    Time frame: Baseline (Pre-CYD vaccination 1) and 28 days after the first CYD dengue vaccination

  3. Percentage of Participants With Neutralizing Antibody Titers Above Predefined Thresholds Against at Least 1, 2, 3, or 4 Serotypes of CYD at Baseline and 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants

    Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (1, 2, 3, and 4) were measured by PRNT50. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain. Percentage of participants with neutralizing antibody titers above pre-defined thresholds (\>=10 and \>=100 \[1/dilution\]) against at least 1, 2, 3, or 4 serotypes of CYD were reported. Here, 'dil'=dilution and "vac"=vaccination in the specified categories.

    Time frame: Baseline (Pre-CYD vaccination 1) and 28 days after the first CYD dengue vaccination

  4. Geometric Mean Concentrations of Serum Antibodies Against Pertussis Antigens (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae 2+3) at Baseline and 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants

    GMCs against each pertussis antigens (PT, FHA, PRN, FIM2+3) were assessed using ELISA assay method and were measured in EU/mL. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.

    Time frame: Baseline (Pre-Tdap vaccination) and 28 days after the Tdap vaccination

  5. Percentage of Participants Achieving Serum Antibody (>=0.1 IU/mL) Against Diphtheria and Tetanus Antigens at Baseline and 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants

    The GMC against diphtheria and tetanus antigens was performed by MIT-TNA and ELISA, respectively. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.

    Time frame: Baseline (Pre-Tdap vaccination) and 28 days after the dose of Tdap vaccination

  6. Number of Participants With Immediate Unsolicited Adverse Events (AE) Following Vaccination With Tdap or CYD Dengue Vaccine

    An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the electronic case report form (eCRF) in terms of diagnosis and/or onset post-vaccination. Any unsolicited AE occurred during first 30 minutes post-vaccination was recorded on the CRF as immediate AE. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccination and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received CYD vaccination.

    Time frame: Within 30 minutes after any and each vaccination

  7. Number of Participants With Solicited Injection Site Reactions Following Vaccination With Tdap or CYD Dengue Vaccine

    A solicited reaction (SR) was an AE observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reactions included pain, erythema, and swelling. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received only CYD vaccination.

    Time frame: Within 7 days after any and each vaccination

  8. Number of Participants With Solicited Systemic Reactions Following Vaccination With Tdap or CYD Dengue Vaccine

    A SR reaction was an AE observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the CRF and considered as related to vaccination. Solicited injection site reactions included fever, headache, malaise, myalgia, and asthenia. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received only CYD vaccination.

    Time frame: Within 14 days after any and each vaccination

  9. Number of Participants Reporting Unsolicited Adverse Events Following Vaccination With Tdap or CYD Dengue Vaccine

    An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset post-vaccination. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received CYD vaccination.

    Time frame: Within 28 days after any and each vaccination

  10. Number of Participants Reporting Non-serious Adverse Event of Special Interests (AESIs) Following Vaccination With Tdap or CYD Dengue Vaccine

    Non-serious AESIs were non-serious AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received CYD vaccination.

    Time frame: Within 7 days post any and each vaccination

  11. Number of Participants Reporting Serious Adverse Events (SAEs) and Serious AESIs Following Vaccination With Tdap or CYD Dengue Vaccine

    SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; required hospitalization or prolonged existing hospitalization; persistent or significant disability/incapacity; congenital anomaly or a medically important event. Serious AESIs were SAEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.

    Time frame: From Day 0 up to 6 months after the last Tdap or CYD vaccination

  12. Number of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Tdap or CYD Dengue Vaccine

    Hospitalized suspected dengue case was defined as an acute febrile illness with diagnosis of dengue requiring hospitalization (with bed attribution). In such cases, 1 unplanned acute blood sample (within the first 5 days after fever onset) was collected for virological confirmation of hospitalized suspected dengue case. A suspected case was considered VCD if there was a detection of wild type dengue virus by dengue non-structural protein 1 antigen ELISA and/or dengue reverse transcriptase-polymerase chain reactions.

    Time frame: From Day 0 up to 6 months after the last Tdap or CYD vaccination

08

Results

Posted Aug 27, 2020
Limitations and caveats
Due to absence of response of competent authorities from The Philippines on protocol amendment, the study was prematurely terminated before injection of last dose (3rd dose) of the CYD dengue vaccine. Objectives related to 3rd dose were not assessed.

Participant flow

Study participants were enrolled from 19 December 2016 to 17 April 2017 at 4 centers in the Philippines. A total of 688 participants were enrolled and randomized in this study.

Participant flow — Overall Study
MilestoneCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Started346342
Safety analysis set (safas)338342
Completed00
Not completed346342
Withdrew: Withdrawal by subject1112
Withdrew: Non-compliance with the protocol308308
Withdrew: Lost to follow-up2722

Outcome measures

PrimaryGeometric Mean Concentrations (GMCs) of Antibodies Against Pertussis Antigens (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae 2+3) 28 Days After Dose of Tdap Vaccine in Previously Dengue Immune Participants

GMCs against each pertussis antigens (pertussis toxoid \[PT\], filamentous hemagglutinin \[FHA\], pertactin \[PRN\], fimbriae types 2 and 3 \[FIM2+3\]) were assessed using an enzyme-linked immunosorbent assay (ELISA) method and were measured in ELISA unit/milliliter (EU/mL). Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.

Time frame:
28 days after Tdap vaccination
Reported as:
Geometric mean · EU/mL
Geometric Mean Concentrations (GMCs) of Antibodies Against Pertussis Antigens (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae 2+3) 28 Days After Dose of Tdap Vaccine in Previously Dengue Immune Participants
EU/mLCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Anti-PT65.2 (57.7 to 73.8)76.0 (67.9 to 85.1)
Anti-FHA273 (248 to 299)267 (241 to 296)
Anti-PRN50.6 (41.4 to 61.9)44.9 (36.7 to 55.0)
Anti-FIM2+3705 (586 to 847)643 (537 to 770)
Statistical analysis
  • CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) vs CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) · Gmc ratio: 0.848 · 95% CI 0.721 to 0.997
  • CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) vs CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) · Gmc ratio: 1.02 · 95% CI 0.892 to 1.18
  • CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) vs CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) · Gmc ratio: 1.11 · 95% CI 0.836 to 1.46
  • CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) vs CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) · Gmc ratio: 1.05 · 95% CI 0.827 to 1.33
PrimaryPercentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants

Seroprotection against diphtheria (Anti-D) and tetanus (Anti-T) antigens was performed by Micrometabolic Inhibition Test - Toxin Neutralization assay (MIT-TNA) and ELISA, respectively. Seroprotection was defined as anti-D and anti-T Ab concentration greater than 0.1 international units (IU)/mL. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.

Time frame:
28 days after Tdap vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants
percentage of participantsCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Anti-D90.1 (86.2 to 93.1)89.8 (85.9 to 92.9)
Anti-T98.4 (96.3 to 99.5)99.0 (97.2 to 99.8)
Statistical analysis
  • CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) vs CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) · Percentage difference: 0.26 · 95% CI -4.53 to 5.04
  • CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) vs CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) · Percentage difference: -0.66 · 95% CI -2.87 to 1.37
PrimaryGeometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants

The GMTs against each of the four parenteral dengue virus serotypes (1, 2, 3 and 4) of CYD dengue vaccine were assessed using the 50% plaque reduction neutralization test (PRNT50) assay method. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain. Titers were measured in terms of 1/dilution.

Time frame:
28 days after first CYD dengue vaccination
Reported as:
Geometric mean · titers
Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants
titersCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Serotype 1513 (427 to 617)461 (384 to 552)
Serotype 2677 (588 to 780)568 (489 to 661)
Serotype 3653 (558 to 765)706 (603 to 828)
Serotype 4378 (324 to 442)472 (404 to 551)
Statistical analysis
  • CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) vs CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) · Gmt ratio: 1.11 · 95% CI 0.862 to 1.44
  • CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) vs CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) · Gmt ratio: 1.19 · 95% CI 0.97 to 1.47
  • CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) vs CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) · Gmt ratio: 0.925 · 95% CI 0.739 to 1.16
  • CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) vs CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) · Gmt ratio: 0.802 · 95% CI 0.644 to 0.999
SecondaryGeometric Mean Titers of Antibodies Against Each Dengue Virus Serotype at Baseline and 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants

The GMTs against each of the four parenteral dengue virus serotypes (1, 2, 3 and 4) of CYD dengue vaccine were assessed using PRNT50 assay method. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain. Titers were measured in terms of 1/dilution.

Time frame:
Baseline (Pre-CYD vaccination 1) and 28 days after the first CYD dengue vaccination
Reported as:
Geometric mean · titers
Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype at Baseline and 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants
titersCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Serotype 1: Pre-vaccination 1265 (218 to 322)250 (208 to 300)
Serotype 1: 28 days post-vaccination 1513 (427 to 616)468 (392 to 560)
Serotype 2: Pre-vaccination 1404 (350 to 467)343 (294 to 401)
Serotype 2: 28 days post-vaccination 1679 (589 to 781)577 (497 to 671)
Serotype 3: Pre-vaccination 1327 (274 to 391)327 (280 to 383)
Serotype 3: 28 days post-vaccination 1655 (559 to 767)709 (605 to 830)
Serotype 4: Pre-vaccination 1136 (115 to 160)172 (150 to 197)
Serotype 4: 28 days post-vaccination 1379 (325 to 443)478 (410 to 557)
SecondaryPercentage of Participants With Neutralizing Antibody Titers Against Each of the 4 Dengue Virus Serotypes of CYD at Baseline and 28 Days After First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants

The GMTs against each of the four parenteral dengue virus serotypes (1, 2, 3 and 4) of CYD dengue vaccine were assessed using PRNT50 assay method. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.

Time frame:
Baseline (Pre-CYD vaccination 1) and 28 days after the first CYD dengue vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Neutralizing Antibody Titers Against Each of the 4 Dengue Virus Serotypes of CYD at Baseline and 28 Days After First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants
percentage of participantsCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Serotype 1: Pre-vaccination 192.7 (89.2 to 95.3)93.3 (90.0 to 95.8)
Serotype 1: 28 days post-vaccination 197.8 (95.4 to 99.1)98.4 (96.3 to 99.5)
Serotype 2: Pre-vaccination 198.1 (95.9 to 99.3)96.5 (93.8 to 98.2)
Serotype 2: 28 days post-vaccination 1100.0 (98.8 to 100.0)99.0 (97.2 to 99.8)
Serotype 3: Pre-vaccination 195.5 (92.6 to 97.5)97.1 (94.6 to 98.7)
Serotype 3: 28 days post-vaccination 1100.0 (98.8 to 100.0)99.7 (98.2 to 100.0)
Serotype 4: Pre-vaccination 193.0 (89.6 to 95.6)97.5 (95.1 to 98.9)
Serotype 4: 28 days post-vaccination 199.4 (97.7 to 99.9)100.0 (98.8 to 100.0)
SecondaryPercentage of Participants With Neutralizing Antibody Titers Above Predefined Thresholds Against at Least 1, 2, 3, or 4 Serotypes of CYD at Baseline and 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants

Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (1, 2, 3, and 4) were measured by PRNT50. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain. Percentage of participants with neutralizing antibody titers above pre-defined thresholds (\>=10 and \>=100 \[1/dilution\]) against at least 1, 2, 3, or 4 serotypes of CYD were reported. Here, 'dil'=dilution and "vac"=vaccination in the specified categories.

Time frame:
Baseline (Pre-CYD vaccination 1) and 28 days after the first CYD dengue vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Neutralizing Antibody Titers Above Predefined Thresholds Against at Least 1, 2, 3, or 4 Serotypes of CYD at Baseline and 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants
percentage of participantsCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
At least 1 Serotype: pre-vac 1: >=10 (1/dil)100.0 (98.8 to 100.0)100.0 (98.8 to 100.0)
At least 1 Serotype: pre-vac1: >=100 (1/dil)97.8 (95.5 to 99.1)97.1 (94.6 to 98.7)
At least 1 Serotype: post-vac 1: >=10 (1/dil)100.0 (98.8 to 100.0)100.0 (98.8 to 100.0)
At least 1 Serotype: post-vac 1: >=100 (1/dil)99.7 (98.2 to 100.0)99.7 (98.2 to 100.0)
At least 2 Serotype: pre-vac 1: >=10 (1/dil)96.5 (93.8 to 98.2)98.1 (95.9 to 99.3)
At least 2 Serotype: pre-vac 1: >=100 (1/dil)84.4 (79.9 to 88.2)87.0 (82.8 to 90.5)
At least 2 Serotype: post-vac 1: >=10 (1/dil)100.0 (98.8 to 100.0)99.7 (98.2 to 100.0)
At least 2 Serotype: post-vac 1: >=100 (1/dil)95.8 (93.0 to 97.8)96.5 (93.8 to 98.2)
At least 3 Serotype: pre-vac 1: >=10 (1/dil)93.6 (90.3 to 96.1)95.2 (92.3 to 97.3)
At least 3 Serotype: pre-vac 1: >=100 (1/dil)76.1 (71.0 to 80.7)76.8 (71.8 to 81.4)
At least 3 Serotype: post-vac 1: >=10 (1/dil)99.7 (98.2 to 100.0)99.4 (97.7 to 99.9)
At least 3 Serotype: post-vac 1: >=100 (1/dil)90.4 (86.6 to 93.4)92.1 (88.5 to 94.8)
At least 4 Serotype: pre-vac 1: >=10 (1/dil)89.2 (85.2 to 92.4)91.1 (87.4 to 94.0)
At least 4 Serotype: pre-vac 1: >=100 (1/dil)52.9 (47.2 to 58.5)54.3 (48.6 to 59.9)
At least 4 Serotype: post-vac 1: >=10 (1/dil)97.4 (95.0 to 98.9)98.1 (95.9 to 99.3)
At least 4 Serotype: post-vac 1: >=100 (1/dil)73.8 (68.6 to 78.6)75.6 (70.4 to 80.2)
SecondaryGeometric Mean Concentrations of Serum Antibodies Against Pertussis Antigens (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae 2+3) at Baseline and 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants

GMCs against each pertussis antigens (PT, FHA, PRN, FIM2+3) were assessed using ELISA assay method and were measured in EU/mL. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.

Time frame:
Baseline (Pre-Tdap vaccination) and 28 days after the Tdap vaccination
Reported as:
Geometric mean · EU/mL
Geometric Mean Concentrations of Serum Antibodies Against Pertussis Antigens (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae 2+3) at Baseline and 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants
EU/mLCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Anti-PT: Pre-vaccination8.46 (7.34 to 9.75)9.56 (8.33 to 11.0)
Anti-PT: 28 days post-vaccination65.0 (57.5 to 73.5)76.1 (68.1 to 85.2)
Anti-FHA: Pre-vaccination19.9 (17.6 to 22.6)19.4 (17.1 to 22.1)
Anti-FHA: 28 days post-vaccination272 (248 to 299)266 (240 to 295)
Anti-PRN: Pre-vaccination3.79 (3.39 to 4.24)3.65 (3.25 to 4.10)
Anti-PRN: 28 days post-vaccination50.6 (41.4 to 61.8)45.0 (36.8 to 55.1)
Anti-FIM2+3: Pre-vaccination15.1 (12.4 to 18.5)14.9 (12.2 to 18.1)
Anti-FIM2+3: 28 days post-vaccination700 (583 to 841)642 (537 to 769)
SecondaryPercentage of Participants Achieving Serum Antibody (>=0.1 IU/mL) Against Diphtheria and Tetanus Antigens at Baseline and 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants

The GMC against diphtheria and tetanus antigens was performed by MIT-TNA and ELISA, respectively. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.

Time frame:
Baseline (Pre-Tdap vaccination) and 28 days after the dose of Tdap vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serum Antibody (>=0.1 IU/mL) Against Diphtheria and Tetanus Antigens at Baseline and 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants
percentage of participantsCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Anti-D: Pre-vaccination31.8 (26.7 to 37.3)32.8 (27.6 to 38.3)
Anti-T: Pre-vaccination63.7 (58.1 to 69.0)69.6 (64.2 to 74.7)
Anti-D: 28 days post-vaccination90.1 (86.2 to 93.2)89.8 (86.0 to 92.9)
Anti-T: 28 days post-vaccination98.1 (95.8 to 99.3)99.0 (97.2 to 99.8)
SecondaryNumber of Participants With Immediate Unsolicited Adverse Events (AE) Following Vaccination With Tdap or CYD Dengue Vaccine

An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the electronic case report form (eCRF) in terms of diagnosis and/or onset post-vaccination. Any unsolicited AE occurred during first 30 minutes post-vaccination was recorded on the CRF as immediate AE. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccination and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received CYD vaccination.

Time frame:
Within 30 minutes after any and each vaccination
Reported as:
Count of participants · Participants
Number of Participants With Immediate Unsolicited Adverse Events (AE) Following Vaccination With Tdap or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Post any vaccination00
Post Tdap vaccination 1 (Visit 1)—0
Post CYD/Tdap vaccination (Visit 2)00
Post CYD vaccination 2 (Visit 4)00
SecondaryNumber of Participants With Solicited Injection Site Reactions Following Vaccination With Tdap or CYD Dengue Vaccine

A solicited reaction (SR) was an AE observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reactions included pain, erythema, and swelling. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received only CYD vaccination.

Time frame:
Within 7 days after any and each vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Injection Site Reactions Following Vaccination With Tdap or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Pain: Post any vaccination229237
Pain: Post Tdap vaccination (Visit 1)—212
Pain: Post CYD/Tdap vaccination (Visit 2)21853
Pain: Post CYD vaccination 2 (Visit 4)6155
Erythema: Post any vaccination1417
Erythema: Post Tdap vaccination (Visit 1)—14
Erythema: Post CYD/Tdap vaccination (Visit 2)135
Erythema: Post CYD vaccination 2 (Visit 4)22
Swelling: Post any vaccination2532
Swelling: Post Tdap vaccination (Visit 1)—30
Swelling: Post CYD/Tdap vaccination (Visit 2)253
Swelling: Post CYD vaccination 2 (Visit 4)22
SecondaryNumber of Participants With Solicited Systemic Reactions Following Vaccination With Tdap or CYD Dengue Vaccine

A SR reaction was an AE observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the CRF and considered as related to vaccination. Solicited injection site reactions included fever, headache, malaise, myalgia, and asthenia. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received only CYD vaccination.

Time frame:
Within 14 days after any and each vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic Reactions Following Vaccination With Tdap or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Fever: Post any vaccination2130
Fever: Post Tdap vaccination (Visit 1)—15
Fever: Post CYD/Tdap vaccination (Visit 2)116
Fever: Post CYD vaccination 2 (Visit 4)109
Headache: Post any vaccination89115
Headache: Post Tdap vaccination (Visit 1)—83
Headache: Post CYD/Tdap vaccination (Visit 2)7033
Headache: Post CYD vaccination 2 (Visit 4)3635
Malaise: Post any vaccination91111
Malaise: Post Tdap vaccination (Visit 1)—81
Malaise: Post CYD/Tdap vaccination (Visit 2)7428
Malaise: Post CYD vaccination 2 (Visit 4)3233
Myalgia: Post any vaccination74100
Myalgia: Post Tdap vaccination (Visit 1)—78
Myalgia: Post CYD/Tdap vaccination (Visit 2)6730
Myalgia: Post CYD vaccination 2 (Visit 4)2622
Asthenia: Post any vaccination6794
Asthenia: Post Tdap vaccination (Visit 1)—69
Asthenia: Post CYD/Tdap vaccination (Visit 2)5924
Asthenia: Post CYD vaccination 2 (Visit 4)1922
SecondaryNumber of Participants Reporting Unsolicited Adverse Events Following Vaccination With Tdap or CYD Dengue Vaccine

An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset post-vaccination. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received CYD vaccination.

Time frame:
Within 28 days after any and each vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Unsolicited Adverse Events Following Vaccination With Tdap or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Post any vaccination5670
Post Tdap vaccination (Visit 1)—40
Post CYD/Tdap vaccination (Visit 2)3720
Post CYD vaccination 2 (Visit 4)2826
SecondaryNumber of Participants Reporting Non-serious Adverse Event of Special Interests (AESIs) Following Vaccination With Tdap or CYD Dengue Vaccine

Non-serious AESIs were non-serious AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received CYD vaccination.

Time frame:
Within 7 days post any and each vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Non-serious Adverse Event of Special Interests (AESIs) Following Vaccination With Tdap or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Post any vaccination00
Post Tdap vaccination (Visit 1)—0
Post CYD/Tdap vaccination (Visit 2)00
Post CYD vaccination 2 (Visit 4)00
SecondaryNumber of Participants Reporting Serious Adverse Events (SAEs) and Serious AESIs Following Vaccination With Tdap or CYD Dengue Vaccine

SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; required hospitalization or prolonged existing hospitalization; persistent or significant disability/incapacity; congenital anomaly or a medically important event. Serious AESIs were SAEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.

Time frame:
From Day 0 up to 6 months after the last Tdap or CYD vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Serious Adverse Events (SAEs) and Serious AESIs Following Vaccination With Tdap or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
SAE811
Serious AESI13
SecondaryNumber of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Tdap or CYD Dengue Vaccine

Hospitalized suspected dengue case was defined as an acute febrile illness with diagnosis of dengue requiring hospitalization (with bed attribution). In such cases, 1 unplanned acute blood sample (within the first 5 days after fever onset) was collected for virological confirmation of hospitalized suspected dengue case. A suspected case was considered VCD if there was a detection of wild type dengue virus by dengue non-structural protein 1 antigen ELISA and/or dengue reverse transcriptase-polymerase chain reactions.

Time frame:
From Day 0 up to 6 months after the last Tdap or CYD vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Tdap or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Number of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Tdap or CYD Dengue Vaccine03

Adverse events

Collected over AE data were collected from Day 0 up to Day 28 post any vaccination. SR data were collected from Day 0 up to Day 14 post-vaccination. The SAEs were collected throughout the trial, i.e. up to 6 months after last Tdap or CYD vaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)0/338 (0%)8/338 (2.4%)248/338 (73.4%)
CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)0/342 (0%)11/342 (3.2%)263/342 (76.9%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Dengue FeverInfections and infestations1/3383/342
GastritisGastrointestinal disorders1/3380/342
AppendicitisInfections and infestations1/3380/342
GastroenteritisInfections and infestations1/3381/342
Cerebral InfarctionNervous system disorders1/3380/342
Abortion CompletePregnancy, puerperium and perinatal conditions1/3380/342
NephrolithiasisRenal and urinary disorders1/3380/342
Rash GeneralisedSkin and subcutaneous tissue disorders1/3380/342
Hypertensive Heart DiseaseCardiac disorders0/3381/342
DyspepsiaGastrointestinal disorders0/3381/342
Most frequent other events
Most frequent other events
EventCYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)
Injection Site PainGeneral disorders229/338237/342
HeadacheNervous system disorders89/338116/342
MalaiseGeneral disorders91/338111/342
MyalgiaMusculoskeletal and connective tissue disorders74/338100/342
AstheniaGeneral disorders67/33894/342
Injection Site SwellingGeneral disorders25/33832/342
PyrexiaGeneral disorders22/33832/342
Upper Respiratory Tract InfectionInfections and infestations17/33817/342

Baseline characteristics

Analysis was performed on all randomized participants.

Age, Continuous
Age, Continuous(years)CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)Total
Mean26.2 ± 16.327.1 ± 16.726.6 ± 16.5
Sex: Female, Male
Sex: Female, Male(Participants)CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)Total
Female187193380
Male159149308
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)Total
Count of participants——0
Dengue Baseline Status
Dengue Baseline Status(Participants)CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)Total
Dengue immune314315629
Dengue non-immune322759
09

Study locations

4 sites
  • Muntinlupa, Alabang, Philippines
  • Manila, 1000, Philippines
  • Quezon City, Philippines
  • Quezon, Philippines
10

References and documents

Publications

  • Santos J, Montellano ME, Solante R, Perreras N, Meyer S, Toh ML, Zocchetti C, Vigne C, Mascarenas C. Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine: Randomized Phase IIIb Trial in Healthy Participants 9-60 Years of Age in the Philippines. Pediatr Infect Dis J. 2021 Sep 1;40(9):856-863. doi: 10.1097/INF.0000000000003220. PubMed 34117198 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Dec 2019, 35 months.

Results were first posted in Aug 2020, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2016
First posted
Dec 14, 2016
StartActual
Dec 19, 2016
Primary completionActual
Dec 10, 2019
CompletionActual
Dec 10, 2019
Results first posted
Aug 27, 2020
Last update
Mar 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02992418
Responsible party
Sponsor
First posted
Dec 14, 2016
Start date
Dec 19, 2016
Primary completion
Dec 10, 2019
Completion
Dec 10, 2019
Results posted
Aug 27, 2020
Last update
Mar 25, 2022

Study contacts

Medical Director
study director · Sanofi Pasteur SA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adacel

Start the discussion